In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the ...

Morningstar brands and products Company Portfolio ...

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis ... findings on histology studies from liver ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver ...